Mosapride

Mosapride is an orally active gastroenterokinetic compound. Mosapride is a 5HT4 agonist. Mosapride is a CYP inducer. Mosapride has a concentration-dependent inhibitory effect on Kv4.3, and its IC50 value is 15.2 μM. Mosapride can be used in the study of gastrointestinal diseases[1][2][3][4][5][6][7].

[1]Tack J, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther. 2012 Apr;35(7):745-67.|[2]Curran MP, et al. Mosapride in gastrointestinal disorders. Drugs. 2008;68(7):981-91.|[3]Kim HS, et al. The effect of mosapride citrate on proximal and distal colonic motor function in the guinea-pig in vitro. Neurogastroenterol Motil. 2008 Feb;20(2):169-76.|[4]Kim YH, et al. Measurement of Human Cytochrome P450 Enzyme Induction Based on Mesalazine and Mosapride Citrate Treatments Using a Luminescent Assay. Biomol Ther (Seoul). 2015 Sep;23(5):486-92.|[5]Uchida M, et al. Dual role of mosapride citrate hydrate on the gastric emptying evaluated by the breath test in conscious rats. J Pharmacol Sci. 2013;121(4):282-7.|[6]Fujisawa M, et al. The 5-HT4 receptor agonist mosapride attenuates NSAID-induced gastric mucosal damage. J Gastroenterol. 2010 Feb;45(2):179-86.|[7]Sung KW, et al. Effect of mosapride on Kv4.3 potassium channels expressed in CHO cells. Naunyn Schmiedebergs Arch Pharmacol. 2013 Oct;386(10):905-16.Chin J Integr Med. 2022 Aug 31.|Drug Metab Pharmacokinet. 2020 Feb;35(1):102-110.|J Ethnopharmacol. 2024 Apr 15:329:118118.|J Appl Microbiol. 2023 Jul 22;lxad153.